Lubrizol’s Apinovex™ polymer was the proud recipient of a Celebration Award in the Pharma Excipients Award category at CPhI China, held in Shanghai, June 24-26. CPhI supports the global Pharma supply chain with multi-channel events and digital platforms in every region, where industry professionals can meet, learn and collaborate on APIs, CDMOs, excipients and more.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250707200302/en/

Lubrizol’s Apinovex™ polymer was the proud recipient of a Celebration Award in the Pharma Excipients Award category at CPhI China, held in Shanghai, June 24-26.

Apinovex polymer's win places it alongside another of Lubrizol's novel excipients, Apisolex™ polymer, with multiple awards, including CPhI’s 2023 Global Innovation Award and recognition as the Grand Winner of the 2023 Annual Medicine Maker Innovation Award. These awards underscore Lubrizol’s commitment to bringing the next generation of excipient technology to market, improving solubility and bioavailability of APIs to enhance drug delivery.

“We are excited to have received this additional recognition from CPhI following the earlier receipt of innovation awards for our novel injectable excipient, Apisolex™ polymer,” says Matt Finkelhor, Global Commercial Manager, Novel Poly­mers, Lubrizol. “The awards confirm that Lubrizol’s innovation is making a difference in drug delivery solutions that improve bioavailability to help bring more life-changing medications to market.”

The CPhI awards include nine award categories across the entire pharmaceutical industry, fully showcasing outstanding achievements in innovation, design, ingredients and excipients. The Pharma Excipients Award recognizes innovative products with high market potential, focusing on improving the technical standards of the pharmaceutical excipients industry, shaping outstanding examples in the global pharmaceutical excipients field, and leading to new trends in industry development.

About Lubrizol

Lubrizol, a Berkshire Hathaway company, is a science-based company whose specialty chemistry delivers sustainable solutions to advance mobility, improve well-being and enhance modern life. Every day, the innovators of Lubrizol strive to create extraordinary value for customers at the intersection of science, market needs and business success, driving discovery and creating breakthrough solutions that enhance life and make the world work better. Founded in 1928, Lubrizol has global reach and local presence, with over 100 manufacturing facilities, sales and technical offices and over 7,000 employees worldwide. For more information, visit www.lubrizol.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250707200302/en/

Apinovex™ polymer's win places it alongside another Lubrizol novel excipient, Apisolex™ polymer, with multiple awards, including CPhI’s 2023 Global Innovation Award and recognition as the Grand Winner of the 2023 Annual Medicine Maker Innovation Award.